New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes

A.H. Sahebkar, Gerald Watts

    Research output: Contribution to journalReview article

    95 Citations (Scopus)

    Abstract

    Background: Reduction in plasma low-density lipoprotein cholesterol (LDL-C) is a fundamental treatment for the prevention of acute coronary syndromes (ACS). Although statin therapy confers significant protection against ACS in both primary and secondary prevention, a considerable residual risk remains after intensive therapy. In addition, a significant proportion of high-risk patients do not achieve the optimal LDL-C goal recommended in the current guidelines (
    Original languageEnglish
    Pages (from-to)1082-1098
    JournalClinical Therapeutics
    Volume35
    Issue number8
    DOIs
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes'. Together they form a unique fingerprint.

    Cite this